FDA Asks Input on Controlling Nasty New Synthetic Drugs Globally
Published Date: 2/27/2026
Notice
Summary
The FDA is asking for your thoughts on new international rules to control some powerful drugs like N-Pyrrolidino Isotonitazene and MDMB-FUBINACA. These changes could affect drug makers, distributors, and countries worldwide by tightening how these substances are made and shared. Comments are open until March 5, 2026, so jump in now to help shape the U.S. stance before a big UN meeting in March!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Controls aimed at protecting public health
The U.N. Committee recommended adding N‑Pyrrolidino Isotonitazene and N‑Desethyl Etonitazene to Schedule I (1961), retaining coca leaf in Schedule I (1961), and adding MDMB‑FUBINACA to Schedule II (1971). The substances are described in the notice as highly potent, linked to fatal overdoses, and without recognized therapeutic use; the proposals will be considered at the CND meeting March 9–13, 2026.
International manufacturing and distribution limits
The U.N. review recommends international manufacturing and distribution restrictions for several substances, including N‑Pyrrolidino Isotonitazene, N‑Desethyl Etonitazene, MDMB‑FUBINACA, and coca leaf. These recommendations will be considered at the U.N. meeting March 9–13, 2026, and could tighten how makers and distributors handle those substances.
No additional U.S. domestic scheduling needed
The notice states that N‑Pyrrolidino Isotonitazene and N‑Desethyl Etonitazene are already controlled in Schedule I under the U.S. Controlled Substances Act and would not require additional permanent domestic controls if placed in Schedule I internationally. It also states MDMB‑FUBINACA is controlled in Schedule I under the CSA and would not require additional permanent domestic controls if placed in Schedule II internationally, and that domestic scheduling actions for coca leaf will not be necessary regardless of the international vote.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03913 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on March 31 and April 1, 2026, to review important grant applications. These meetings protect private info and trade secrets while deciding who gets funding for exciting health research. Scientists and applicants should note these dates as they impact which projects get money and support.
Next: 2026-03915 — Self-Regulatory Organizations; The Options Clearing Corporation; Notice of Filing of Proposed Rule Change by The Options Clearing Corporation Concerning a Change in Types of Acceptable Collateral and an Update To Mitigate Wrong-Way Risk
The Options Clearing Corporation (OCC) is updating its rules to stop accepting two types of rarely used collateral and to better protect itself from risky situations where things could go wrong at the same time. This change affects the financial firms that use OCC to clear their options trades and helps keep the system safer without changing costs right now. The new rules were proposed in February 2026 and are open for public comments before they take effect.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in